Press release
United Therapeutics Corporation Reports First Quarter 2021 Financial Results
Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug
About this update from United Therapeutics Corporation
[{"type":"text","content":"Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD)\n Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration\n TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021\n\n\nSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. \n\"2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity® Pump for Remodulin®,\" said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. \"In addition to these product launches and the potential Tyvaso DPI approval in December, we are progressing our late-stage pipeline with the commencement of the pivotal TETON study of Tyvaso in IPF, continued enrollment of the pivotal PERFECT study of Tyvaso in PH-COPD, and the ongoing pivotal ADVANCE studies of ralinepag.\" \n\"Following approval in late March, we're already gaining traction with physicians for Tyvaso in PH-ILD, with patient referrals and starts beginning in April,\" said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. \"The commercial launch of Tyvaso in PH-ILD builds on the momentum we're already seeing for the Remunity Pump for Remodulin, which provides significant improvements over legacy subcutaneous delivery options.\"\nFIRST QUARTER 2021 FINANCIAL RESULTS \nKey financial highlights include (dollars in millions, except per share data):\nThree Months Ended \nMarch 31,\nDollar Change\nPercentage Change\n2021\n2020\nRevenues\n$\n379.1\n$\n356.3\n$\n22.8\n6\n%\nNet income\n$\n28.3\n$\n137.7\n$\n(109.4)\n(79)\n%\nNon-GAAP earnings(1)\n$\n162.1\n$\n159.2\n$\n2.9\n2\n%\nNet income, per basic share\n$\n0.63\n$\n3.14\n$\n(2.51)\n(80)\n%\nNet income, per diluted share\n$\n0.61\n$\n3.12\n$\n(2.51)\n(80)\n%\nNon-GAAP earnings, per diluted share(1)\n$\n3.49\n$\n3.61\n$\n(0.12)\n(3)\n...